Search Results - "Jayne, David RW"

Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial by Howman, Andrew, MMath, Chapman, Tracey L, Langdon, Maria M, MSc, Ferguson, Caroline, BSc, Adu, Dwomoa, MD, Feehally, John, Prof, Gaskin, Gillian J, PhD, Jayne, David RW, MD, O'Donoghue, Donal, Prof, Boulton-Jones, Michael, FRCP, Mathieson, Peter W, Prof

“…Summary Background Membranous nephropathy leads to end-stage renal disease in more than 20% of patients. Although immunosuppressive therapy benefits some…”
Get full text

Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a systematic review by Xiao, Yingqi, Guyatt, Gordon, Zeng, Linan, RW Jayne, David, A Merkel, Peter, AC Siemieniuk, Reed, Dookie, Jared E, A Buchan, Tayler, Ahmed, Muhammad Muneeb, J Couban, Rachel, Mahr, Alfred, Walsh, Michael

“…ObjectiveTo compare the efficacy and safety of alternative glucocorticoids (GCs) regimens as induction therapy for patients with antineutrophil cytoplasmic…”
Get full text

Rituximab for treatment of severe renal disease in ANCA associated vasculitis by Geetha, Duvuru, Hruskova, Zdenka, Segelmark, Marten, Hogan, Jonathan, Morgan, Matthew D., Cavero, Teresa, Eriksson, Per, Seo, Philip, Manno, Rebecca L., Dale, Jessica, Harper, Lorraine, Tesar, Vladimir, Jayne, David RW

“…Background Rituximab (RTX) is approved for remission induction in ANCA associated vasculitis (AAV). However, data on use of RTX in patients with severe renal…”
Get full text

Anaemia, weight loss, and round shadows in the lungs by Thakor, Avnesh S, Dr, Hiemstra, Thomas F, MRCP, Jayne, David RW, FRCP

“…In February, 2007, a 70-year-old man visited his general practitioner after 6 weeks of weight loss, shortness of breath on slight exertion, and night sweats. 3…”
Get full text

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial by Jones, Rachel B, Furuta, Shunsuke, Tervaert, Jan Willem Cohen, Hauser, Thomas, Luqmani, Raashid, Morgan, Matthew D, Peh, Chen Au, Savage, Caroline O, Segelmark, Marten, Tesar, Vladimir, van Paassen, Pieter, Walsh, Michael, Westman, Kerstin, Jayne, David Rw

“…The RITUXVAS trial reported similar remission induction rates and safety between rituximab and cyclophosphamide based regimens for antineutrophil cytoplasm…”
Get more information

Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study by Rathmann, Jens, Jayne, David, Segelmark, Mårten, Jönsson, Göran, Mohammad, Aladdin J

“…Abstract Objective To determine the incidence rate, predictors and outcome of severe infections in a population-based cohort of ANCA-associated vasculitis…”
Get full text

Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease by Roberts, Darren M, Jones, Rachel B, Smith, Rona M, Alberici, Federico, Kumaratne, Dinakantha S, Burns, Stella, Jayne, David R.W

“…Abstract Rituximab is a B cell depleting monoclonal antibody used to treat lymphoma and autoimmune disease. Hypogammaglobulinemia has occurred after rituximab…”
Get full text

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis by Jones, Rachel B, Cohen Tervaert, Jan Willem, Hauser, Thomas, Luqmani, Raashid, Morgan, Matthew D, Peh, Chen Au, Savage, Caroline O, Segelmark, Mårten, Tesar, Vladimir, van Paassen, Pieter, Walsh, Michael, Walsh, Dorothy, Westman, Kerstin, Jayne, David R.W

“…A standard glucocorticoid regimen plus rituximab was not superior to standard intravenous cyclophosphamide as induction therapy in patients with newly…”
Get full text

Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis by Wechsler, Michael E., Nair, Parameswaran, Terrier, Benjamin, Walz, Bastian, Bourdin, Arnaud, Jayne, David R.W., Jackson, David J., Roufosse, Florence, Börjesson Sjö, Lena, Fan, Ying, Jison, Maria, McCrae, Christopher, Necander, Sofia, Shavit, Anat, Walton, Claire, Merkel, Peter A.

“…In this randomized trial, benralizumab was noninferior to mepolizumab for the induction of remission in patients with relapsing or refractory eosinophilic…”
Get full text

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial by de Groot, Kirsten, Harper, Lorraine, Jayne, David R W, Flores Suarez, Luis Felipe, Gregorini, Gina, Gross, Wolfgang L, Luqmani, Rashid, Pusey, Charles D, Rasmussen, Niels, Sinico, Renato A, Tesar, Vladimir, Vanhille, Philippe, Westman, Kerstin, Savage, Caroline O S

“…Current therapies for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis are limited by toxicity. To compare pulse cyclophosphamide with daily…”
Get full text

SP133IGA VASCULITIS (HENOCH-SCHÖNLEIN PURPURA): REFRACTORY AND RELAPSING DISEASE COURSE IN THE ADULT POPULATION by Van de Perre, Els, Jones, Rachel B, Jayne, David Rw

Get full text

The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease by Marco, Helena, Smith, Rona M, Jones, Rachel B, Guerry, Mary-Jane, Catapano, Fausta, Burns, Stella, Chaudhry, Afzal N, Smith, Kenneth G C, Jayne, David R W

“…Rituximab is a B cell depleting anti-CD20 monoclonal antibody. CD20 is not expressed on mature plasma cells and accordingly rituximab does not have immediate…”
Get full text

Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group by Jayne, D R, Rasmussen, N

“…The diagnosis, treatment, and monitoring of the primary systemic vasculitides associated with circulating antineutrophil cytoplasm autoantibodies (ANCA) have…”
Get more information

Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19 by Fisk, Marie, Althage, Magnus, Moosmang, Sven, Greasley, Peter J., Cope, Andrew P., Jayne, David RW, Galloway, James, Hall, Frances, Wilkinson, Ian B., Ambery, Philip, Cheriyan, Joseph

“…The novel coronavirus 2019 (COVID-19) infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global pandemic that requires a…”
Get full text

Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: A case series by Roberts, Darren M, Jones, Rachel B, Smith, Rona M, Alberici, Federico, Kumaratne, Dinakantha S, Burns, Stella, Jayne, David R.W

“…Abstract The anti-CD20 B cell depleting monoclonal antibody rituximab is being used increasingly for autoimmune diseases, including patients with refractory…”
Get full text

The characterisation and determinants of quality of life in ANCA associated vasculitis by Basu, Neil, McClean, Andrew, Harper, Lorraine, Amft, Esther Nicole, Dhaun, Neeraj, Luqmani, Raashid A, Little, Mark A, Jayne, David Rw, Flossmann, Oliver, McLaren, John, Kumar, Vinod, Erwig, Lars P, Reid, David M, Jones, Gareth T, Macfarlane, Gary J

“…To contextualise and identify the determinants of poor health related quality of life (QOL) among patients with antineutrophil cytoplasm antibody (ANCA)…”
Get more information

Anti-B Cell Antibody Therapies for Inflammatory Rheumatic Diseases by Faurschou, Mikkel, Jayne, David R.W

“…Several monoclonal antibodies targeting B cells have been tested as therapeutics for inflammatory rheumatic diseases. We review important observations from…”
Get full text

Progress in treatment of ANCA-associated vasculitis by Smith, Rona M, Jones, Rachel B, Jayne, David R W

“…Autoantibodies to neutrophil cytoplasmic antigen-associated vasculitis (AAV) is characterised by inflammation of blood vessels. The introduction of…”
Get full text

Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody–associated vasculitis by Alberici, Federico, MD, Smith, Rona M., MD, Fonseca, Mariana, PhD, Willcocks, Lisa C., PhD, Jones, Rachel B., MD, Holle, Julia U., PhD, Wieczorek, Stefan, MD, Neumann, Thomas, PhD, Martorana, Davide, PhD, Gregorini, Gina, MD, Sinico, Renato A., MD, Bruchfeld, Annette, PhD, Gunnarsson, Iva, PhD, Ohlsson, Sophie, PhD, Baslund, Bo, PhD, Tesar, Vladimir, PhD, Hruskova, Zdenka, PhD, Cid, Maria C., PhD, Vaglio, Augusto, PhD, Lyons, Paul A., PhD, Smith, Kenneth G.C., PhD, Jayne, David R.W., MD

“…To the Editor: Rituximab is effective at inducing and maintaining remission in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).1,2 The…”
Get full text

Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis by GUERRY, Mary-Jane C. J, BROGAN, Paul, WATTS, Richard A, JAYNE, David R. W, BRUCE, Ian N, D'CRUZ, David P, HARPER, Lorraine, LUQMANI, Raashid, PUSEY, Charles D, SALAMA, Alan D, SCOTT, David G. I, SAVAGE, Caroline O. S

“…To perform a literature review and develop recommendations for the use of rituximab in ANCA-associated vasculitis. A committee of experts (five…”
Get full text